A PYMNTS Company

Novo Nordisk Caps Insulin Prices in Settlement with Minnesota Attorney General

By  |  January 27, 2025
The Commission’s Paper on the Obligation of Continuous Supply of Medicines and it’s Impact on Parallel Exporting Activities in The EU

Novo Nordisk, a leading Danish pharmaceutical company, has agreed to cap insulin prices as part of a settlement with Minnesota’s attorney general, who accused the three largest insulin manufacturers of inflating the drug’s cost to astronomical levels. The settlement, filed Monday in a Newark, New Jersey federal court, follows similar agreements reached last year with Eli Lilly and French drugmaker Sanofi, according to Reuters.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Under the terms of the settlement, Novo Nordisk will limit out-of-pocket expenses for patients who pay cash to $35 per monthly prescription, regardless of insurance status. Additionally, the company will provide free insulin to low-income Minnesotans with annual household incomes at or below 400% of the federal poverty level—approximately $128,600 for a family of four. The settlement, which lasts five years, is still pending court approval. Per Reuters, Novo Nordisk denied any wrongdoing in reaching the agreement.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Read more: Massachusetts AG Sues Insulin Makers and PBMs Over Alleged Price-Fixing Scheme

    Minnesota Attorney General Keith Ellison, who filed lawsuits against Novo Nordisk, Eli Lilly, and Sanofi, accused the companies of prioritizing profits over patients by setting artificially high list prices and using rebates to negotiate lower prices with pharmacy benefit managers. Insulin, a life-saving drug used by patients with type 1 diabetes and some with type 2 diabetes, has seen its costs skyrocket in recent years. According to Ellison, these settlements mark a significant step toward affordable access to insulin, with reductions in patient costs exceeding 90%.

    Eli Lilly and Sanofi reached their respective settlements with Minnesota in February and July 2024. At a press conference, Ellison emphasized the human impact of these legal victories, stating, “For years, manufacturers prioritized making billions in profits over saving lives.”

    Novo Nordisk expressed satisfaction with the agreement. A company spokesperson noted that the settlement underscores its dedication to ensuring affordable insulin access. The company, which has U.S. offices in Plainsboro, New Jersey, joins Eli Lilly and Sanofi in facing scrutiny for price-setting practices that allegedly burdened patients relying on insulin to manage their condition.

    The lawsuits targeted the manufacturers’ practice of using the wholesale acquisition cost—or list price—as the basis for determining out-of-pocket costs, which plaintiffs argued led to inflated expenses for consumers.

    Source: Reuters